Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IIIverson, everything is a go..keep up the good work!
IIIverson, you missed my point.. I felt having a picture of Jerry crossed the line, not what you said..
IIIverson, that may have crossed the line just a little..
The filing of the NDA in July should be worth +$.50 to +$.60. Mr. Market will long forget the turmoil in the stock today..
Quote:
I believe taken in total, the OS ranged from more than two months to about 22 months, depending on the form of Sarcoma the pts had. How in the world could you rationalize any differently the way Ariad worded it?
OVERALL SURVIVAL RANGED FROM TWO TO TWENTY TWO MONTHS
The success of ridaforolimus in extending progression-free survival was already known, but updated data show that patients are likely to live longer when taking the drug. Although the follow-up in the study is continuing, it showed a survival benefit of more than two months to about 22 months, as of the data cut-off in the fall. Merck is conducting an analysis, and an update to the survival data will be presented at the June meeting, an Ariad spokeswoman said
I think the $25 million we receive for the filing of the NDA for Rida in July from Merck, will take out some of the sting..
The success of ridaforolimus in extending progression-free survival was already known, but updated data show that patients are likely to live longer when taking the drug. Although the follow-up in the study is continuing, it showed a survival benefit of more than two months to about 22 months, as of the data cut-off in the fall. Merck is conducting an analysis, and an update to the survival data will be presented at the June meeting, an Ariad spokeswoman said.
It's all within the realm of other drug companies. This is all you can achieve sometimes:
News for 'ARIA' - (*DJ AstraZeneca's Olaparib Delayed Cancer's Return Or Death By Nearly 4 Months)
(MORE TO FOLLOW) Dow Jones Newswires
May 18, 2011 18:00 ET (22:00 GMT)
Dow Jones Newswire is more optimistic:
A late-stage study of ridaforolimus, developed by Ariad Pharmaceuticals with partner Merck & Co. (MRK), showed success as a maintenance therapy in advanced sarcoma, a group of cancers that forms in connective tissue.
The drug, which blocks a central regulator within cancer cells so that they essentially starve, was given to patients with stable disease after chemotherapy. It works in a similar manner as Afinitor from Novartis AG (NVS, NOVN.VX) and Torisel from Pfizer. Merck has said it will file for FDA approval by year-end.
The success of ridaforolimus in extending progression-free survival was already known, but updated data show that patients are likely to live longer when taking the drug. Although the follow-up in the study is continuing, it showed a survival benefit of more than two months to about 22 months, as of the data cut-off in the fall.
Merck is conducting an analysis, and an update to the survival data will be presented at the June meeting, an Ariad spokeswoman said.
-Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com
The Street:
New details also emerged Wednesday from a phase III study of Ariad Pharmaceuticals' sarcoma drug ridaforolimus. While a survival analysis of the study is still ongoing, patients treated with ridaforolimus have to date reported a median overall survival of 88 weeks compared to a median overall survival of 79 weeks for placebo-treated patients. The 8% relative reduction in the risk of death favoring ridaforolimus is not yet statistically significant.
Ariad and its partner Merck(MRK_) previously announced meeting the study's primary endpoint -- a statistically significant, 28% reduction in the risk of tumor progression that favored ridaforolimus over placebo. Ariad and Merck will be seeking approval for ridaforolimus later this year.
If it was Goldman, you would have my attention..
Certainly, with all the present and future indications from all three of their compounds, the market cap should be well north of $1 billion..
Yes, I'm very familiar with point-and-figure charting. Some people swear by it.. To me, it is just another tool..
I just sent the article (link) for the board to chew on.. That's all... Also notice all the stocks begin with "A". I think it is another way to obtain your email for who knows what..
I think this stuff has a 50-50 chance of being right, but here it is for the TA folks on this board (and, you know who you are!): Article mentions that Ariad is at a point-and-figure triple top.
http://www.healthtalkandyou.com/pf-triple-top-breakout-acas-alte-amgn-aria-asca/
Closed at the low of the day for the last several days.. I just don't like it......
You almost couldn't ask for better media coverage.. Although this is getting close to my Berger on the front cover of BusinessWeek topping process..
http://www.investorplace.com/40937/biotech-stock-to-buy-ariad-pharmaceuticals-inc-nasdaq-aria/
News for 'ARIA' - (joh Changes EPS Estimate of ARIAD PHARMACEUTICALS INC)
May 13, 2011 (Nelson's Broker Summaries via COMTEX) --
Company: ARIAD PHARMACEUTICALS INC
Report Headline: "Ariad Pharmaceuticals : Model Update"
Report Date: May 10, 2011
Current FY EPS Estimate [FY2011]: -0.81
Previous EPS Estimate for Current FY [FY2011]: N/A
Current Quarter EPS Estimate [Q2]: -0.16
Previous EPS Estimate for Current Quarter [Q2]: -0.15
Next FY EPS Estimate [FY2012]: -0.49
Previous EPS Estimate for Next FY [FY2012]: -0.49
Current Recommendation: OVERWEIGHT
Research Firm: joh
Analyst: CORY KASIMOV
Industry: HEALTH/BIOTECH
Estimates reported in USD
http://www.thomsonfinancial.com
Copyright 2011, Nelson Information, a Thomson Financial company
-0-
Ariad could be the next Biotech Star, from the moneyshow, FWIW:
http://www.moneyshow.com/investing/article/1/tptp051211-23080/Ariad-Could-Be-Next-Biotech-Star/
The Big Money's Favorite Growth Stocks
see #10
http://seekingalpha.com/article/269293-the-big-money-s-favorite-growth-stocks?source=email_watchlist
Partnering Pona in Asia is a given. It may be Harvy's slight change in position to partner in the EU (thanks poster for finding the time in harvey's presentation yesterday) is a positioning ploy. However, with the expansion of their pipeline (Pona for AML, potentially for solid tumors), and with new indications for their compounds, including '113, beyond NSCLC, partnering will still be a strategic option for Ariad with their limited resources...
Harv on the B of A presentation today had a different response to how they market to the EU. Last CC, he said they would market Pona in the US and EU and partner in Asia. This time, and listen to what he said, he said they are "still deciding" about the EU, but they will file the NDA in both the US and EU. Not that this means that much...
With all the resourcefull individuals here, I'm surprised no one has discovered and posted the new research report from JPM's Cory Kasimov...
JPM's Cory KASIMOV has a new research report out this morning, but I do not have access. He is still overweight, and we are over $9, so hopefully someone can provide us the skinny..
Company: ARIAD PHARMACEUTICALS INC
Report Headline: "Ariad Pharmaceuticals : 1Q Snapshot; Story Advancing at a Rapid PACE"
Report Date: May 05, 2011
Current FY EPS Estimate [FY2011]: -0.62
Previous EPS Estimate for Current FY [FY2011]: -0.62
Current Quarter EPS Estimate [Q2]: -0.13
Next FY EPS Estimate [FY2012]: -0.46
Previous EPS Estimate for Next FY [FY2012]: -0.46
Current Recommendation: OVERWEIGHT
Research Firm: joh
Analyst: CORY KASIMOV
Industry: HEALTH/BIOTECH
The big difference is that those two stocks were coming out of a big bear market.. Ariad, which is already up strong, is not..
Or, like this chart.. But, make no mistake.. it will be a step function..then I'm out..
http://finance.yahoo.com/echarts?s=HGSI+Interactive#symbol=HGSI;range=5y
I expect that we will find a day that this happens to us in the not to distant future:
http://finance.yahoo.com/echarts?s=DNDN+Interactive#chart2:symbol=dndn;range=5y;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined
adreamer, I'm impressed as Ariad was at $.90 for just two weeks over the last 5 years:
http://finance.yahoo.com/echarts?s=ARIA+Interactive#chart6:symbol=aria;range=5y;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined
Ariad and Exelixis look to shine at ASCO- Biomedreports:
http://biomedreports.com/2011050966876/ariad-and-exelixis-look-to-shine-at-asco-2011.html
bth, you missed it.. this is the reason for the conflict.. has absolutely nothing to do with being on boards:
He also serves as a director of Leerink Swann LLC, an independent healthcare research firm..
Leerink Swann LLC is on all the CC's and has a price target for Ariad...kapesh?
Aught-Oh, a slight conflict:
AspenTech Appoints Robert M. Whelan, Jr. to Board of Directors
May 6, 2011 09:00:04 (ET)
BURLINGTON, Mass., May 06, 2011 (BUSINESS WIRE) -- Aspen Technology, Inc. (AZPN, Trade ), a leading provider of software and services to the process industries, announced that Robert M. Whelan, Jr. has been appointed to the company's board of directors.
-- Whelan brings an extensive background of technology investment banking and executive management to AspenTech's board. Since 2001, he has been President of Whelan & Company, LLC, providing business and financial consulting and strategic services to a broad range of companies. From 2001 to 2005, he served as Managing Director of the consulting firm Valuation Perspectives, Inc.
-- Previously, Whelan held a number of senior-level positions at leading investment banking and brokerage firms. He was Vice Chairman of Prudential Volpe Technology Group, the technology investment banking and research division of Prudential Securities. Prior to Prudential Volpe, he was Chief Operating Officer, Managing Director, board member and Head of Investment Banking of Volpe Brown Whelan & Company, a private technology and healthcare investment banking, brokerage and asset management firm acquired by Prudential Securities in late 1999.
[b]-- Whelan currently serves as a director of ARIAD Pharmaceuticals, Inc. (ARIA, Trade ), a developer of small-molecule drugs to treat patients with aggressive cancers where current therapies are inadequate. He also serves as a director of Leerink Swann LLC, an independent healthcare research firm, and Growth Capital Partners L.P., an advisory and asset management firm. He is a former member of the board of directors of Coastal Enterprise Ventures, a socially responsible venture fund in Portland, Maine.
-- Whelan holds an MBA from Stanford University and a BA from Dartmouth College.
FDA Okays Everolimus for Rare Type of Pancreatic Cancer
Adds some more value to the Rida franchise..
http://www.medscape.com/viewarticle/742274
The approval is based on results from a clinical trial, previously reported by Medscape Medical News, of 410 patients with metastatic or locally advanced disease. Those that received everolimus experienced a median of 11 months before tumor growth compared with 4.6 months in participants who were given a placebo. Patients taking everolimus experienced a 65% lower risk for cancer progression than those receiving placebo (hazard ratio, 0.35 [95% confidence interval, 0.27 - 0.45]; P < .001), according to data released by Novartis.
JPM should be on this Monday-Tuesday,imho.. They will not let this get away from them..